10-Q: Moleculin Biotech Reports Second Quarter 2024 Results, Advances Annamycin to Phase 3 Trial

Moleculin Biotech's Q2 2024 results show a net loss, but the company is progressing Annamycin to a Phase 3 trial for AML treatment.

Summary

• Moleculin Biotech reported a net loss of $4.319 million for the three months ended June 30, 2024, and a net loss of $9.289 million for the six months ended June 30, 2024.
• The company's research and development expenses were $4.090 million for the three months and $8.342 million for the six months ended June 30, 2024.
• General and administrative expenses were $2.064 million for the three months and $4.457 million for the six months ended June 30, 2024.
• A gain from the change in fair value of warrant liability was $1.696 million for the three months and $3.151 million for the six months ended June 30, 2024.
• The company had cash and cash equivalents of $10.845 million as of June 30, 2024.
• Moleculin is planning a Phase 3 MIRACLE trial for Annamycin in combination with Cytarabine for the treatment of relapsed or refractory AML.
• The MIRACLE trial will initially focus on 2nd line treatment for R/R AML subjects and then follow-up with treatment for 3rd line R/R AML.
• The company expects to begin the MIRACLE trial in Q1 2025 and have interim data by mid-2026.
• The company has received Orphan Drug Designation from the EMA for Annamycin for the treatment of AML.
• The company has filed an S-1 with the SEC indicating intentions to raise $12 million via the issuance of equity.

Sentiment

Score: 7

Explanation: The document presents a mix of positive and negative aspects. The progress of Annamycin to a Phase 3 trial and the promising efficacy data are strong positives. However, the company's financial situation, ongoing SEC investigation, and dependence on future capital raises are significant concerns. The overall sentiment is cautiously optimistic.

Positives

• Annamycin is progressing to a Phase 3 trial, indicating potential for regulatory approval.
• The MIRACLE trial design is adaptive, allowing for dose optimization based on initial results.
• Preliminary data from the MB-106 trial shows promising efficacy for Annamycin in AML.
• Annamycin has demonstrated a lack of cardiotoxicity, a significant advantage over other anthracyclines.
• The company has secured key patents for Annamycin, providing commercial exclusivity.
• The EMA's Orphan Drug Designation for Annamycin provides potential benefits.
• The company is exploring external funding for other drug candidates, reducing financial burden.
• The company has a clear timeline for the MIRACLE trial, with key milestones identified.

Negatives

• The company reported a net loss of $9.289 million for the six months ended June 30, 2024.
• The company's cash on hand of $10.8 million is not sufficient to fund operations for at least one year.
• The company is dependent on raising additional capital to continue operations.
• The company is subject to an ongoing SEC investigation, which could result in further expenses and uncertainty.
• The company has not generated any revenues from operations.
• The company has a history of losses and an accumulated deficit of $140.9 million since inception.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing.
• There is no guarantee that the company will be successful in raising the $12 million via the issuance of equity.
• The company is subject to an ongoing SEC investigation, which could result in penalties or other adverse actions.
• Clinical trials may not be successful, and drug candidates may not receive regulatory approval.
• The company is dependent on third-party manufacturers for drug production.
• The company faces competition from existing and emerging therapies.
• The company may experience delays in regulatory review and approval of drug candidates.
• The company's intellectual property rights may not be adequately protected.

Future Outlook

The company plans to initiate a Phase 3 MIRACLE trial for Annamycin in Q1 2025 and expects to have interim data by mid-2026. They also intend to raise additional capital through an equity offering. The company believes that its existing cash and cash equivalents as of June 30, 2024, along with the cash expected from this raise will be sufficient to fund its planned operations into the second quarter of 2025.

Management Comments

• Management believes that anthracyclines represent the most important treatment for AML and Advanced STS.
• Management believes Annamycin may allow a majority of these patients to benefit from this treatment.
• Management believes the Phase 1B/2 trial has been successful in establishing safety and efficacy of Annamycin in combination with Cytarabine (AnnAraC) for the treatment of AML.
• Management believes the results demonstrated by AnnAraC in 2nd line subjects substantially exceeds the performance reported by any drug currently approved for use in 2nd line AML.

Industry Context

The company is focused on developing treatments for hard-to-treat cancers and viruses, which aligns with the broader industry trend of targeting unmet medical needs. The development of Annamycin, a next-generation anthracycline with reduced cardiotoxicity, addresses a significant limitation of existing chemotherapy options. The company's focus on investigator-led studies and external funding also reflects a common strategy in the biotech industry to leverage resources and expertise.

Comparison to Industry Standards

• The reported 50% CR rate and 60% CRc rate in 2nd line AML subjects in the MB-106 trial is significantly higher than the typical response rates seen with currently approved therapies in this setting. For example, standard chemotherapy regimens for relapsed/refractory AML often achieve CR rates in the range of 20-30%.
• The lack of cardiotoxicity observed with Annamycin is a major differentiator compared to traditional anthracyclines like doxorubicin, which are known to cause significant cardiac damage. This could position Annamycin as a safer alternative for patients who are at risk of or have pre-existing cardiac conditions.
• The company's approach of using a lipid-based delivery technology for Annamycin is similar to other companies that are developing novel drug delivery systems to improve efficacy and reduce toxicity. However, Moleculin's specific lipid composition and its demonstrated lack of cardiotoxicity appear to be unique.
• The company's strategy of pursuing Orphan Drug Designation for Annamycin is a common practice in the biotech industry to secure market exclusivity and other benefits for drugs targeting rare diseases. This is similar to companies like Agios Pharmaceuticals and Blueprint Medicines who have successfully leveraged ODD for their oncology drugs.
• The company's reliance on external funding for some of its programs is a common practice for smaller biotech companies. This is similar to companies like Xencor and Arcus Biosciences who have partnered with larger pharmaceutical companies or academic institutions to advance their drug candidates.

Related Party Transactions

• The company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expenses of $59,000 for each of the three months ended June 30, 2024 and 2023, respectively, and $117,000 for the six months ended June 30, 2024 and 2023, respectively.
• The company recorded approximately $12,000 in sublease income from a related party for the three months ended June 30, 2024 and 2023, respectively, and $24,000 and $25,000 for the six months ended June 30, 2024 and 2023.
• Accounts payable includes $20,000 and $67,000 as of June 30, 2024 and December 31, 2023, respectively, for related party payables.
• Related party receivables were $4,000 as of June 30, 2024 and December 31, 2023.
• Accrued liabilities due to related party were $44,000 and $60,000 as of June 30, 2024 and December 31, 2023.

Stakeholder Impact

• Shareholders may be impacted by the potential equity raise and the company's financial performance.
• Employees may be impacted by the company's ability to secure funding and continue operations.
• Patients with AML may benefit from the development of Annamycin.
• Suppliers and creditors may be impacted by the company's financial stability.
• The company's success could lead to increased value for shareholders and potential job creation.

Next Steps

• Begin contracting with MIRACLE trial sites in 2024 2H.
• Treat the first subject in the MIRACLE trial in 2025 Q1.
• Provide a recruitment update (n=40) in 2025 Q4.
• Unblind interim data (n=75) and set the Optimum Dose for the MIRACLE trial in mid-2026.
• Begin enrollment of 3rd line subjects in MIRACLE2 in 2026.
• End enrollment in 2nd line subjects in 2027.
• Obtain final data for 2nd line subjects in MIRACLE in 2028.
• Begin submission of a new drug application (NDA) for the treatment of R/R AML in 2028 2H.

Key Dates

Keywords

Annamycin, AML, Acute Myeloid Leukemia, Clinical Trial, Phase 3, MIRACLE Trial, Cardiotoxicity, Orphan Drug Designation, Warrant Liability, Drug Development, Biotechnology, Oncology, Cytarabine, R/R AML, Regulatory Approval